Epic as an Effective, Low Toxicity Salvage Therapy for Patients with Poor Risk Lymphoma Prior to Beam High Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation

References

• Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMillan A. K., Chopra R., Milligan D., Vaughan Hudson G. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet; 1993; 341: 1051–54
   PubMed Web of Science ®Google Scholar
• Chopra R., McMillan A. K., Linch D. C., Yuklea S., Taghipour G., Pearce R., Patterson K G., Goldstone A. H. The place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor risk Hodgkin's disease. A single centre eight-year study of 155 patients. Blood 1993; 81(no 5)1137–1145
   PubMed Web of Science ®Google Scholar
• Philip T., Guglielmi C., Hagenbeek A., Somers R., Van Der Lelie H., Bron D., Sonneveld P., Gisselbrecht C., Cahn J. Y., Harousseau J. L., Coiffer B., Biron P., Mandelli F., Chauvin F. Autologous bone marrow transplantation as compared to salvage chemotherapy in relapses of Chemotherapy sensitive non-Hodgkin's lymphoma. New England Journal of Medicine 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Chopra R., Linch D. C., McMillan A. K., Blair S., Patterson K. G., Moir D., Richards J M., Cervi P., Kinsey S., Goldstone A. H. Mini-Beam followed by BEAM and ABMT for very poor risk Hodgkin's disease. British Journal of Haemtology 1992; 81: 197–202
   PubMed Web of Science ®Google Scholar
• Prince H. M., Imrie K., Chrump M., Stewart K., Girouard C., Colwill R., Brabdwein J., Tsang R. W., Gerald Scott J., Sutton D. M. C., Pantalony D., Carstairs K., Sutcliffe S. B., Keating A. The role of intensive therapy an autologous blood and marrow transplantation for chemotherapy sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. British Journal of Haemtology; 1996; 92: 880–889
   PubMed Web of Science ®Google Scholar
• Sweetenham JW., Taghipour G., Milligan D., Blystad A. K., Caballero D., Fassas A., Goldstone A. H. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplantation 1997; 20: 745–52
   PubMed Web of Science ®Google Scholar
• Hickish T., Roldan A., Cunningham D., Mansi J., Ashley S., Nicolson V., Gore M. E., Catovsky D., Smith I. E. EPIC: an effective low toxicity regimen for relapsing lymphoma. British. Journal of Cancer 1993; 81: 1137–145
   Google Scholar
• Richardson D. S., Tighe M., Cull M., Johnson S. A., Phillips M. J. Salvage chemotherapy for Relapsed and Resistant Lymphoma with a Carboplatin Containing Schedule - EPIC. Haemtological Oncology 1994; 12: 125–128
   PubMed Web of Science ®Google Scholar
• Millar A. B., Hoogstraten B., Staquet M., Winklre A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Philip T., htage J. O., Spitzer G., Chauvin F., Jagan-Nath S., Cahn J. Y., Colombat P., Goldstone A. H., Gorin N. C., Flesh H., Laporte J. P., Maraninchi D., Pico J., Bosly A., Anderson C., Schots R., Biron P., Cabanillas F., Dicke K. High dose chemotherapy and autologous bone marrow transplanlation after failure of conventional chemotherpy in adults with inttermediate-grade or high-grade non-Hodgkin's lymphoma. New England Journal of Medicine 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Philip T., Biron P., Maraninchi D., Gastaut J. A., Herve P., Flesh Y., Goldstone A. H., Souhami R. L. Role of massive chemotherapy and autologous bone marrow transplantation in Non-Hodgkin's malignant lymphoma. Lancet 1984; 1: 391
   PubMed Web of Science ®Google Scholar
• Mills W., Chopra R., McMillan A., Pearce R., Linch D. C., Goldstone A. H. BEAM chemotherapy with autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology 1995; 13: 588–595
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Sullivan K. M., Buckner C. D., Clift R. A., Deeg H. J., Fefer A., Hill R., Mortimer J., Neiman P. E., Sanders J. E. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology 1987; 5(9)1340–7
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., McLaughlin P., Tucker S., Hagemeister F. B., Swan F., Rodriguez M. A., Romaguera J., Rubenstein E., Cabanillas F. ESHAP- An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. Journal of Clinical Oncology 1994; 12(No 6)1169–1179
   PubMed Web of Science ®Google Scholar
• Girouard C., Dufresne I., Imrie K., Stewart A. K., Brand-Wein J., Prince H. M., Pantolony D., Keating A., Crump M. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Annals of Oncology. 1997; 8(7)675–80
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P., McLaughin P., Fridrik M., Tucker S., Jagannath S., Hagemeister EB., Redman J. R., Swan F., Barlogie B. Effective salvage therapy for lymphoma with ciplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Wilson W. H., Bryant G., Bates S., Fojo A., Wittes R. E., Steinberg S. M., Kohler D. R., Jaffe E. S., Herdt J., Cheson B. D., Chabner B. A. EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology 1993; 11: 1573–82
   PubMed Web of Science ®Google Scholar
• Child J. A., Johnson S. A. N., Smith G. M., Johnson P. W. M., Prentice A. G. Fludarabine enhanced dexamethasone, cytosine and cisplatinum for recurrent I refractory aggressive Non-Hodgkin's Lymphoma. Blood 88, (suppl 1) abstr 2267. 1996
   Google Scholar
• Grigg A., Chapman R., Szer J. Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine. Bone Marrow Transplantation. 1998; 21(6)619–21
   PubMed Web of Science ®Google Scholar